- Home
- GMAB vs PFGC Comparison
GMAB vs PFGC Comparison
Compare GMAB & PFGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PFGC
- Stock Information
- Founded
- GMAB 1999
- PFGC 1885
- Country
- GMAB Denmark
- PFGC United States
- Employees
- GMAB N/A
- PFGC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PFGC Food Distributors
- Sector
- GMAB Health Care
- PFGC Consumer Discretionary
- Exchange
- GMAB Nasdaq
- PFGC Nasdaq
- Market Cap
- GMAB 13.7B
- PFGC 13.7B
- IPO Year
- GMAB N/A
- PFGC 2015
- Fundamental
- Price
- GMAB $21.45
- PFGC $95.13
- Analyst Decision
- GMAB Buy
- PFGC Strong Buy
- Analyst Count
- GMAB 8
- PFGC 10
- Target Price
- GMAB $37.80
- PFGC $99.90
- AVG Volume (30 Days)
- GMAB 1.6M
- PFGC 1.1M
- Earning Date
- GMAB 08-07-2025
- PFGC 08-13-2025
- Dividend Yield
- GMAB N/A
- PFGC N/A
- EPS Growth
- GMAB 276.80
- PFGC N/A
- EPS
- GMAB 18.36
- PFGC 2.41
- Revenue
- GMAB $3,230,902,140.00
- PFGC $57,949,200,000.00
- Revenue This Year
- GMAB $747.74
- PFGC $17.93
- Revenue Next Year
- GMAB $14.81
- PFGC $5.91
- P/E Ratio
- GMAB $11.66
- PFGC $39.35
- Revenue Growth
- GMAB 25.43
- PFGC 7.20
- 52 Week Low
- GMAB $17.24
- PFGC $61.90
- 52 Week High
- GMAB $28.56
- PFGC $96.02
- Technical
- Relative Strength Index (RSI)
- GMAB 53.47
- PFGC 74.89
- Support Level
- GMAB $20.23
- PFGC $87.86
- Resistance Level
- GMAB $21.90
- PFGC $88.89
- Average True Range (ATR)
- GMAB 0.35
- PFGC 1.78
- MACD
- GMAB 0.06
- PFGC 0.57
- Stochastic Oscillator
- GMAB 73.52
- PFGC 92.62
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PFGC Performance Food Group Company
Performance Food Group Co , markets and distributes national and company-branded food and food-related products. The company also specializes in distributing candy, snacks, beverages, cigarettes, other tobacco products, health and beauty care products and other items to vending distributors, box retailers, theaters, convenience stores, drug stores, grocery stores, travel providers, and hospitality providers. The company has three reportable segments: Foodservice, Vistar, and Convenience.